🇺🇸 FDA
Patent

US 11352435

Anti-CD133 monoclonal antibodies and related compositions and methods

granted A61KA61K2039/505A61P

Quick answer

US patent 11352435 (Anti-CD133 monoclonal antibodies and related compositions and methods) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61P, A61P35/00